This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The benchmark Philippine Stock Exchange index (PSEi) managed to close with a small gain on Wednesday, a day after inflation fears eased with the release of data for May.
GTCAP GTCXY GTMEY BDOUY BDOUF JBFCF PHSXY GTMEF PSE SPHXF SPHZF GLOPA AYAAF PSKXF AYAAY JBFCY GLOPP SMPH BDO GLO SPHXY JFC BBRRF BLOOM ALI LTG
In a country which is 80 percent Catholic, it would seem surprising that the gaming industry has taken off: the Philippines has become one of the key markets for casinos in Asia after Macau and Singapore.
0027 BBRRF BLOOM GXYEF GXYYY 42R
THE RAZON group’s Sureste Properties, Inc. is proposing to build a P308-million dock for cruise ships in Parañaque City, a project that has been elevated to the Office of the President, the Tourism Infrastructure and Enterprise Zone Authority (TIEZA) said Tuesday.
ICT BBRRF ICTEF BLOOM
The Tourism Infrastructure and Enterprise Zone Authority (TIEZA) has submitted to Malacanang a proposal to construct a P308-million Manila cruise port in Paranaque City.
ICT BBRRF ICTEF BLOOM
Integrated gaming report operator Bloomberry Resorts Corp. saw a 71-percent year-on-year surge in first quarter net profit to a new quarterly high of P3.7 billion, boosted by an unusually large windfall from Solaire casino’s high-roller segment.
BLOOMBERRY Resorts Corp. reported a 73% increase in attributable profit for the first three months of 2018, boosted by record volumes in both its mass gaming and VIP gaming segments.
Integrated gaming report operator Bloomberry Resorts Corp. saw a 71-percent year-on-year surge in first quarter net profit to a new quarterly high of P3.7 billion, on record high gaming revenues from Solaire, the first gaming hub to open at Pagcor Entertainment City along Manila Bay.
Bloomberry Resorts Corp reported a 73% increase in attributable profit for the first three months of 2018, boosted by record volumes in both mass gaming and VIP gaming segments.
In 2016, a mysterious syndicate tried to steal $951 million from Bangladesh’s central bank - and laid bare a profound weakness in the system by which money moves around the world.
WFCNP DB RZLLY WFC.PRL WFC.PRJ RCB BAESF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN INSY BA WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC BAESY WFC.WS NYTAB 532210 MCWPF CUB BBRRF BLOOM
Observers expect home prices in the Philippines capital to get a boost from the steady stream of Chinese workers catering not only to offshore gaming customers, but also mainland clients who frequent bricks-and-mortar casinos
SMPH CBG SPHXY AYAAY SPHXF BBRRF SPHZF BLOOM DD CBRE ALI AYAAF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET